Abstract:UNLABELLED:We have previously reported that the removal of a 20-nucleotide sequence, termed the D sequence, from both ends of the inverted terminal repeats (ITRs) in the adeno-associated virus serotype 2 (AAV2) genome significantly impairs rescue, replication, and encapsidation of the viral genomes (X. S. Wang, S. Ponnazhagan, and A. Srivastava, J Mol Biol 250:573-580, 1995; X. S. Wang, S. Ponnazhagan, and A. Srivastava, J Virol 70:1668-1677, 1996). Here we describe that replacement of only one D sequence in either ITR restores each of these functions, but DNA strands of only single polarity are encapsidated in mature progeny virions. Since most commonly used recombinant AAV vectors contain a single-stranded DNA (ssDNA), which is transcriptionally inactive, efficient transgene expression from AAV vectors is dependent upon viral second-strand DNA synthesis. We have also identified a transcription suppressor sequence in one of the D sequences, which shares homology with the binding site for the cellular NF-κB-repressing factor (NRF). The removal of this D sequence from, and replacement with a sequence containing putative binding sites for transcription factors in, single-stranded AAV (ssAAV) vectors significantly augments transgene expression both in human cell lines in vitro and in murine hepatocytes in vivo. The development of these genome-modified ssAAV vectors has implications not only for the basic biology of AAV but also for the optimal use of these vectors in human gene therapy.IMPORTANCE:The results of the studies described here not only have provided novel insights into some of the critical steps in the life cycle of a human virus, the adeno-associated virus (AAV), that causes no known disease but have also led to the development of novel recombinant AAV vectors which are more efficient in allowing increased levels of gene expression. Thus, these studies have significant implications for the potential use of these novel AAV vectors in human gene therapy.

Mar-Binding Proteins.

Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses

High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA–Polylysine Complexes

A novel application of baculovirus in mammalian gene therapy]

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Enhanced Transgene Expression from Recombinant Single-Stranded D-sequence-substituted Adeno-Associated Virus Vectors in Human Cell Lines in Vitro and in Murine Hepatocytes in Vivo.

Adenovirus as a Vector and Oncolytic Virus

Single Plasmid-Based, Upgradable, and Backward-Compatible Adenoviral Vector Systems

Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications

Characterization of an Adenovirus Vector Containing a Heterologous Peptide Epitope in the HI Loop of the Fiber Knob

AAV-Based Targeting Gene Therapy

Adeno-Associated Virus Engineering and Load Strategy for Tropism Modification, Immune Evasion and Enhanced Transgene Expression

Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells

Functional Characterization of a PEI-CyD-FA-coated Adenovirus As Delivery Vector for Gene Therapy.

Adenovirus Mediates Lentiviral Vector Entry for Gene Delivery

Preliminary Study of Mini-Adenovirus S ystem

Expanding the Scope of Adenoviral Vectors by Utilizing Novel Tools for Recombination and Vector Rescue

Covalently linked adenovirus-AAV complexes as a novel platform technology for gene therapy

Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures

Replicative recombinant human 55-type Adenovirus vector and preparation method and application thereof

Generation of targeted adeno-associated virus (AAV) vectors for human gene therapy.